- Home
- HOLO vs ITRM Comparison
HOLO vs ITRM Comparison
Compare HOLO & ITRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HOLO | ITRM |
|---|---|---|
| Founded | 2018 | 2015 |
| Country | China | Ireland |
| Employees | 64 | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.8M | 24.3M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | HOLO | ITRM |
|---|---|---|
| Price | $1.96 | $0.03 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | 654.7K | ★ 27.6M |
| Earning Date | 08-10-2023 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 57.43 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $947.65 |
| P/E Ratio | $0.16 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.36 | $0.03 |
| 52 Week High | $12.75 | $1.42 |
Technical Indicators
Market Signals| Indicator | HOLO | ITRM |
|---|---|---|
| Relative Strength Index (RSI) | 43.16 | 26.10 |
| Support Level | N/A | N/A |
| Resistance Level | $2.37 | $0.39 |
| Average True Range (ATR) | 0.17 | 0.02 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 25.51 | 3.34 |
Price Performance
Historical ComparisonAbout HOLO MicroCloud Hologram Inc.
MicroCloud Hologram Inc, through its subsidiaries, is mainly engaged in holographic Technology. It includes Holographic solutions and Holographic technology services. The company also provides holographic digital twin technology services for customers and has built a holographic digital twin technology resource library. Geographically company is operating in single segment, China.
About ITRM Iterum Therapeutics plc
Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.